Illumina Continues Push into Clinic with MiSeq Panels, HiSeq 2500, Reorganization | GenomeWeb

Illumina is continuing its push into the clinical next-generation sequencing space. Customers are validating MiSeq panels for clinical use; HiSeq 2500 purchases are increasing from commercial, translational, and hospital customers; and the firm's recently announced reorganization is aiming to further drive the company into the clinic, President and CEO Jay Flatley said this week during a conference call discussing Illumina's third quarter earnings.

Additionally, the company is still negotiating with BGI on a clinical sequencing contract.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.